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Objectives: To review clinical outcomes of endovascu-
lar treatment of type B aortic dissection.
Methods: All patients treated for type B aortic dissec-
tion between 2006-2011 were identified from a prospec-
tively maintained registry. Health systems charts and med-
ical correspondences were reviewed. Measured outcomes
included resolution of the indication for intervention, ad-
ditional procedures, and survival at 30 days and 1 year.
Results: 55 patients were treated with TEVAR for type
B dissection (mean age, 6114 years), 39 (71%) for acute
dissections and 16 (29%) for chronic dissections. Indica-
tions for treatment were pain (21), malperfusion (13),
aneurysm (6), uncontrolled hypertension (6), expansion
(5), and rupture (4). Success, defined by relief of indication
and freedom from death or re-intervention at 30 days, was
achieved in 87% of patients. Twenty-six additional proce-
dures were performed in 22 patients prior to, or at the time
of TEVAR. These included debranching procedures (8),
renal stenting (7), Iliac stenting (5), iliac exposure or
conduit creation (2), mesenteric stenting (2), thrombec-
tomy (1), and tube thoracostomy (1). Left subclavian ar-
tery coverage was required in 23 patients. Spinal ischemia
occurred in 4 patients, and lumbar drainage performed in 2
patients. Three patients required reintervention during the
study period. Survival was 93% at thirty-days and 78% at
one year.
Conclusions: TEVAR is effective in the treatment of
the complications of both acute and chronic type B aortic
dissection. Additional procedures are frequently necessary,
but early results indicate favorable outcomes, while re-
intervention is rare.
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Objectives: Although dextran has been theorized to
diminish the risk of stroke after carotid endarterectomy-
(CEA) variation exists in its use. We evaluated outcomes of
dextran use in patients undergoing CEA to clarify its utility.
Methods: We studied all primary CEA performed by
71 surgeons within the Vascular Study Group of New
England database (2003-2010). Patients were stratified by
perioperative dextran use. Outcomes included periopera-
tive death, stroke, myocardial infarction(MI) and conges-
tive heart failure(CHF). Group and propensity score
matching were performed for risk adjusted comparisons,
and multivariable logistic regression was used to examine
associations between dextran use and outcomes.
Results: There were 6,641 CEA performed, with dex-
tran used in 334(5%) procedures. Dextran and No Dextran
patients were similar in age(70 years) and symptomatic
status(25%). Other differences between the cohorts dimin-
ished after adjustment (Table). In crude, group-matched,
and propensity matched analyses, stroke/death rate was
similar between cohorts (1.2%),while Dextran patients
were more likely to suffer perioperative MI (2.4% vs 1.0%;
Table.
EVAR OAR
Male (n1820) Female (n453) P value Male (n1436) Female (n484) P value
Age (years), median
All 74 77 .001 71 73 .001
Intact 74 76 .001 70 73 .001
Ruptured 72 78 .001 73 77 .001
AAA diameter (mm), mean
All 58.4 56.6 .004 64.7 59.7 .001
Elective 57.2 55.4 .001 60.8 57.3 .001
Symptomatic 65.4 62.5 0.39 69.3 65.4 .24
Ruptured 75.3 72.4 0.56 79.1 70.8 .004
30-day mortality (%)
All 2 2 0.46 8 9 .39
Intact 1 1 .58 2 4 .05
Ruptured 29 26 1.00 33 48 .03
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P.029) and CHF (2.1% vs 0.6%; P.005). In multivar-
iate analysis, dextran was associated with a higher risk of
perioperative MI (OR, 5.2; CI,1.9-14.4; P.002) and
CHF (OR, 5.9; CI,1.9-18.5; P0.002).
Conclusions: Dextran use was not associated with
perioperative stroke but was associated with higher rates of
MI and CHF. Taken together, our findings suggest limited
clinical utility for dextran.
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Objectives: CMS requires high risk criteria for CAS
reimbursement. The impact of these criteria on outcomes
remains uncertain, potentially biasing comparative effec-
tiveness analysis. We evaluate this using data from the SVS
Vascular Registry™.
Methods: We analyzed 10,107 patients undergoing
CEA (6370) and CAS (3737). Patients were stratified by
CMS high risk (HR) criteria. The primary endpoint was
composite death, stroke and MI (MACE) at 30 days.
Results: CAS patients were more likely to have preop-
erative stroke (26 v 21%) or TIA (23 v 19%) than CEA.
While age 80years was similar, CAS had higher preva-
lence of all other HR criteria. For CEA, HR patients had
higher MACE than normal risk: SX (7.3 v 4.6%, P.01)
and ASX (5 vs 2.2%; P.0001). For CAS there was no
difference: SX (9.1 vs 6.2%; P.24) or ASX (5.4 vs 4.2%;
P.61) All CAS patients had MACE rates similar to HR
CEA. After risk adjustment, CAS had higher rates than
CEA for MACE (OR, 1.2; 95%CI, 1.0-1.5), death (1.5,
1.0-2.2) and stroke (1.3, 1.0-1.7), while there was no
difference in MI (OR, 0.8, 0.6-1.3). Multivariate analyses
for predictors of MACE are reported in the Table. Radia-
tion and restenosis were protective for MACE from CAS.
Conclusions: CEA is safer in the majority of patients
with carotid disease. Normal risk CAS may be confined to
restenosis and radiation.
Table. Multivariate logistic models for 30-day MACE
CEA - Risk factors
Odds
ratio 95% CI P value
Symptomatic 1.831 1.426-2.351 .0001
Age 80y 1.370 1.024-1.833 .0341
CHF class III/IV 1.707 1.027-2.839 .0392
LVEF 30% 3.529 1.620-7.690 .0015
Angina 3.920 1.545-9.942 .0040
Contralateral occlusion 3.164 2.112-4.738 .0001
High anatomic lesion 2.723 1.321-5.616 .0067
CAS - Risk factors
Odds
ratio 95% CI P value
Symptomatic 1.674 1.292-2.170 .0001
Recent MI 3.433 1.674-7.043 .0008
Restenosis 0.591 0.430-0.813 .0012
Prior radiation to neck 0.418 0.225-0.776 .0057
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Table.
Characteristics
Crude sample Group matched sample Propensity matched sample
Dextran, %
(n443)
No Dextran, %
(n6397) P value
Dextran, %
(n333)
No Dextran, %
(n1523) P value
Dextran, %
(n334)
No Dextran, %
(n1670) P value
General
Anesthesia
74.3 88.9 .001 74.5 79.3 0.06 74.3 73.5 .84
Eversion 19.2 10.0 .001 19.2 24.7 0.03 19.2 19.2 .99
Shunt 18.9 48.6 .001 18.9 20.1 0.65 18.9 23.2 .10
Outcomes
Stroke or death 1.2 1.0 .58 1.2 0.6 0.27 1.2 0.7 .32
MI 2.4 1.0 .03 2.4 0.6 0.005 2.4 0.5 .003
CHF 2.1 0.6 .005 2.1 0.5 0.006 2.1 0.2 .001
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